Kirsi Santti1, Annette Beule2, Laura Tuomikoski2, Mikko Rönty3, Anna-Stina Jääskeläinen2, Kauko Saarilahti2, Hanna Ihalainen4, Maija Tarkkanen2, Carl Blomqvist2. 1. Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, PO Box 180, 00029 HUS, Helsinki, Finland. kirsi.santti@hus.fi. 2. Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, PO Box 180, 00029 HUS, Helsinki, Finland. 3. Department of Pathology, HUSLAB and University of Helsinki, Helsinki, Finland. 4. Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: Desmoid tumors (aggressive fibromatosis) are rare soft tissue tumors which frequently recur after surgery. Desmoid tumors arise from musculoaponeurotic tissue in the extremities, head and neck, abdominal wall, or intra-abdominally. Our aim was to examine the outcome of radiotherapy of desmoid tumors in a single institution series. PATIENTS AND METHODS: We evaluated 41 patients with desmoid tumors treated with 49 radiotherapies between 1987 and 2012. Radiologic images for response evaluation were reassessed and responses to treatment registered according to RECIST criteria 1.1. For patients with local failures radiation dose distribution was determined in each local failure volume using image co-registration. Recurrences were classified as in-target, marginal, or out-of-target. Prognostic factors for radiotherapy treatment failure were evaluated. RESULTS: Radiotherapy doses varied from 20-63 Gy (median 50 Gy) with a median fraction size of 2 Gy. The objective response rate to definitive radiotherapy was 55% (12/22 patients). Median time to response was 14 months. A statistically significant dose-response relation for definitive and postoperative radiotherapy was observed both in univariate (p-value 0.002) and in multivariate analysis (p-value 0.02) adjusted for potential confounding factors. Surgery before radiotherapy or surgical margin had no significant effect on time to progression. Nine of 11 (82%) local failures were classified as marginal and two of 11 (18%) in-target. None of the recurrences occurred totally out-of-target. CONCLUSIONS: Radiotherapy is a valuable option for treating desmoid tumors. Radiotherapy dose appears to be significantly associated to local control.
BACKGROUND:Desmoid tumors (aggressive fibromatosis) are rare soft tissue tumors which frequently recur after surgery. Desmoid tumors arise from musculoaponeurotic tissue in the extremities, head and neck, abdominal wall, or intra-abdominally. Our aim was to examine the outcome of radiotherapy of desmoid tumors in a single institution series. PATIENTS AND METHODS: We evaluated 41 patients with desmoid tumors treated with 49 radiotherapies between 1987 and 2012. Radiologic images for response evaluation were reassessed and responses to treatment registered according to RECIST criteria 1.1. For patients with local failures radiation dose distribution was determined in each local failure volume using image co-registration. Recurrences were classified as in-target, marginal, or out-of-target. Prognostic factors for radiotherapy treatment failure were evaluated. RESULTS: Radiotherapy doses varied from 20-63 Gy (median 50 Gy) with a median fraction size of 2 Gy. The objective response rate to definitive radiotherapy was 55% (12/22 patients). Median time to response was 14 months. A statistically significant dose-response relation for definitive and postoperative radiotherapy was observed both in univariate (p-value 0.002) and in multivariate analysis (p-value 0.02) adjusted for potential confounding factors. Surgery before radiotherapy or surgical margin had no significant effect on time to progression. Nine of 11 (82%) local failures were classified as marginal and two of 11 (18%) in-target. None of the recurrences occurred totally out-of-target. CONCLUSIONS: Radiotherapy is a valuable option for treating desmoid tumors. Radiotherapy dose appears to be significantly associated to local control.
Entities:
Keywords:
Aggressive fibromatosis; Dose-response relationship, radiation; Local recurrence; Radiotherapy
Authors: Mika M Sampo; Laura Tuomikoski; Maija Tarkkanen; Anna-Stina Jääskeläinen; Erkki J Tukiainen; Annette Beule; Mikko Tenhunen; Tom O Böhling; Carl P Blomqvist Journal: Acta Oncol Date: 2013-11-08 Impact factor: 4.089
Authors: Robert A Zlotecki; Mark T Scarborough; Christopher G Morris; B Hudson Berrey; D Scott Lind; William F Enneking; Robert B Marcus Journal: Int J Radiat Oncol Biol Phys Date: 2002-09-01 Impact factor: 7.038
Authors: K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: Emma J Groen; Annemieke Roos; Friso L Muntinghe; Roelien H Enting; Jakob de Vries; Jan H Kleibeuker; Max J H Witjes; Thera P Links; André P van Beek Journal: Ann Surg Oncol Date: 2008-07-09 Impact factor: 5.344
Authors: Brigitta G Baumert; Martin O Spahr; Arthur Von Hochstetter; Sylvie Beauvois; Christine Landmann; Katrin Fridrich; Salvador Villà; Michael J Kirschner; Guy Storme; Peter Thum; Hans K Streuli; Norbert Lombriser; Robert Maurer; Gerhard Ries; Ernst-Arnold Bleher; Alfred Willi; Juerg Allemann; Ulrich Buehler; Hugo Blessing; Urs M Luetolf; J Bernard Davis; Burkhardt Seifert; Manfred Infanger Journal: Radiat Oncol Date: 2007-03-07 Impact factor: 3.481
Authors: Andrew J Bishop; Jace P Landry; Christina L Roland; Ravin Ratan; Barry W Feig; Bryan S Moon; Maria A Zarzour; Wei-Lien Wang; Alexander J Lazar; Valerae O Lewis; Keila E Torres; B Ashleigh Guadagnolo Journal: Cancer Date: 2020-04-28 Impact factor: 6.860